MUC1 Dendritic Cell Vaccine
Identification
- Generic Name
- MUC1 Dendritic Cell Vaccine
- DrugBank Accession Number
- DB05477
- Background
Dendritic Cell (DC) Therapy is a newly emerging and potent form of immune therapy that amplifies the actions of the body's own immune system to help fight cancer, AIDS and other serious conditions. The Dendritic Cell is an immune cell whose role is the recognition, processing and presentation of foreign antigens to the T-cells to initiate a primary response in the effector arm of the immune system. Dendritic cells not only activate lymphocytes to induce the immune response, but they also minimize autoimmune reactions by downplaying self-antigens to stimulated T-cells. Dendritic Cell Therapy involves the harvesting of blood cells (ie monocytes or macrophages) from a patient and processing them in the laboratory to produce a greater than typical Dendritic Cell concentration. These cells are then given back to a patient as a vaccine in order to allow for a potent immune response to cancer.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Vaccines
Other vaccines - Synonyms
- Not Available
Pharmacology
- Indication
Investigated for use/treatment in cancer/tumors (unspecified) and ovarian cancer.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
The Dendritic Cell is an immune cell whose role is the recognition, processing and presentation of foreign antigens to the T-cells to initiate a primary response in the effector arm of the immune system. Dendritic Cell Therapy involves the harvesting of blood cells (ie monocytes or macrophages) from a patient and processing them in the laboratory to produce a greater than typical Dendritic Cell concentration. These cells are then given back to a patient as a vaccine in order to allow for a potent immune response to cancer.
- Mechanism of action
Use of increased concentration of dendritic cells to amplify immune responses to cancer.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Cancer Vac / Cancer Vac Mannan-MUC1 / CVac
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Whiteside TL, Odoux C: Dendritic cell biology and cancer therapy. Cancer Immunol Immunother. 2004 Mar;53(3):240-8. Epub 2003 Dec 18. [Article]
- Conrad C, Nestle FO: Dendritic cell-based cancer therapy. Curr Opin Mol Ther. 2003 Aug;5(4):405-12. [Article]
- Vermorken JB, Van Tendeloo VF: Dendritic cell therapy of cancer: can it fulfill its promise? Expert Rev Anticancer Ther. 2003 Feb;3(1):1-3. [Article]
- Reinhard G, Marten A, Kiske SM, Feil F, Bieber T, Schmidt-Wolf IG: Generation of dendritic cell-based vaccines for cancer therapy. Br J Cancer. 2002 May 20;86(10):1529-33. [Article]
- Grolleau A, Sloan A, Mule JJ: Dendritic cell-based vaccines for cancer therapy. Cancer Treat Res. 2005;123:181-205. [Article]
- External Links
- PubChem Substance
- 347910162
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Active Not Recruiting Treatment Astrocytoma, Grade IV / Brain Cancer / Brain Neoplasm / Glioblastoma Multiforme (GBM) / Glioma / High Grade Glioma: Glioblastoma (GBM) 1 3 Withdrawn Treatment Prostate Cancer 1 2 Completed Treatment Epithelial Ovarian Cancer 2 2 Completed Treatment High Grade Glioma: Glioblastoma (GBM) 1 2 Recruiting Prevention Malaria 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
- Not Available
Drug created at November 18, 2007 18:25 / Updated at June 12, 2020 16:52